

# CAMLIN FINE CHEMICALS LIMITED

Regd. Office: Camlin Fine Chemicals Ltd., ICC Chambers, 3<sup>rd</sup> Floor, Saki Vihar Road  
Mumbai 400072. Tel: 28479609/9610

**AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2008**

Rupees in Lacs

Sr. No.	Particulars	Nine Month Ended 31.12.2007 (Reviewed)	Quarter Ended		Year Ended		Consolidated for the Year Ended 31.03.2008 (Audited)
			31.03.2008 (Reviewed)	31.03.2007 (Reviewed)	31.03.2008 (Audited)	31.03.2007 (Audited)	
1	Net Sales/Income from Operations	5,855.59	2,272.44	1,551.75	8,128.03	4,789.18	8,140.57
2	Other Income	55.33	2.59	57.63	57.92	177.49	57.69
3	Total Income	5,910.92	2,275.03	1,609.38	8,185.95	4,966.67	8,198.26
4	Expenditure						
	a) Increase/Decrease in Closing Stock & W.I.P	(95.22)	(119.41)	(7.31)	(214.63)	(117.49)	(214.22)
	b) Consumption of Materials	3,345.03	1,470.98	1,091.79	4,816.01	3,311.05	4,825.34
	c) Purchase of Traded Goods	78.85	(37.16)	(90.38)	41.69	25.79	41.69
	d) Employee Cost	305.56	127.44	82.51	433.00	232.04	433.79
	e) Depreciation	276.68	103.08	75.26	379.76	208.44	380.37
	f) Other Expenditure	1,336.23	479.63	578.46	1,815.86	1,317.32	1,844.90
	g) Total Expenditure (a+b+c+d+e+f)	5,247.13	2,024.56	1,730.33	7,271.69	4,977.15	7,311.87
5	Interest	366.25	131.45	81.37	497.70	221.72	498.59
6	Exceptional items	-	-	-	-	-	-
7	Profit(+)/Loss(-) from Ordinary Activities Before Tax(3)-(4+5+6)	297.54	119.02	(202.32)	416.56	(232.20)	387.80
8	Provision for Taxation						
	a) Wealth Tax	-	0.07	0.21	0.07	0.21	0.07
	b) Current (Mat Provision)	30.63	14.00	-	44.63	-	44.63
	Less Mat Credit Entitlement	(30.63)	(12.41)	-	(43.04)	-	(43.04)
	c) - Deferred	92.07	33.52	(52.59)	125.59	(62.01)	125.11
	- Fringe Benefit	9.50	2.77	5.01	12.27	11.96	12.45
9	Net Profit(+)/Loss(-) From Ordinary Activities after Tax(7-8)	195.97	81.07	(154.95)	277.04	(182.36)	248.58
10	Extraordinary items (net of tax expense)	-	-	-	-	-	-
11	Net Profit(+)/Loss(-) for the period(9-10)	195.97	81.07	(154.95)	277.04	(182.36)	248.58
12	Minority Interest	-	-	-	-	-	(12.32)
13	Net Profit after Minority Interest & Share of P&L	195.97	81.07	(154.95)	277.04	(182.36)	260.90
14	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	580.00	580.00	485.00	580.00	485.00	580.00
15	Reserves excluding Revaluation Reserves (as per Balance Sheet)				2,124.25	1,510.71	2,108.31
16	Earning per Share (EPS)						
	Basic	3.38	1.59	(4.21)	5.42	(4.96)	5.10
	Diluted	3.29	1.57	-	5.38	-	5.06
17	Public Shareholding						
	Number of Shares	2,496,392	2,870,426	2,452,226	2,870,426	2,452,226	2,870,426
	Percentage of Shareholding	43.04	49.49	50.56	49.49	50.56	49.49

**Notes:**

- 1 "Fine Chemicals Division" of Camlin Limited was merged into the Company w.e.f. 1<sup>st</sup> July 2006. Hence, the figures of Previous year are not comparable with the corresponding figures of the Current year.
- 2 In the light of AS-17 Segmental Reporting, the Company operates in a single business segment namely "Fine Chemicals" and there is no reportable geographical segment.
- 3 Details of utilization of funds during the quarter, out of Rs.574.60 lacs received from the preferential issue of equity Shares & 10% upfront received for equity warrants in December 2007 – as per clause 43 of the Listing Agreement. Capital Expenditure Rs.123.81 lacs . Long Term Investments & Acquisition of Company Rs.41.00 lacs Balance amount utilized for Working Capital Rs. 409.79 lacs
- 4 The consolidated financial results for the year includes figures in respect of Sangam Laboratories Ltd, subsidiary of the Company w.e.f. 22<sup>nd</sup> January 2008, Chemolutions Chemicals Ltd, subsidiary of the company w.e.f. 25<sup>th</sup> March 2008 and Dulcette Technologies LLC, joint venture company w.e.f. 13th April 2007.
- 5 Effect of AS-15(Revised) issued by Institute of Chartered Accountants of India relating to the provisions for Employee benefit viz leave encashment, Gratuity etc has complied with.
- 6 There were Nil Investor complaint pending at the beginning of the quarter. The Company did not receive any Investor complaint during the quarter.
- 7 The figures of the previous period have been regrouped/rearranged wherever necessary.
- 8 The Board has recommended a dividend of 10%, subject to approvals of the Shareholders at Annual General Meeting.
- 9 The above results have been reviewed by the Audit Committee and have been taken on record at the meeting of the Board of Directors held on June 26, 2008.

By the Order of the Board



Ashish Dandekar  
Managing Director

Place: Mumbai  
Date: 26<sup>th</sup> June 2008